← Leaderboards
Daniel Roche
University Of Chicago
$1,699,036
Attributed
$2,000,317
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $524.8K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,000,317 · 4
By mechanism
K01$924,860 · 1
R34$602,562 · 1
R21$408,187 · 1
F31$64,708 · 1
Top collaborators
- Melanie E Bennett2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Daniel S McGehee$8,689,091
- Timothy E Koeltzow$59,443
- Harriet De Wit$19,929,985
- Roy E Weiss$3,465,766
- Nancy J. Cox$31,978,299
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsAffectAlcohol Use DisorderPharmacotherapyNational Institute On Alcohol Abuse And AlcoholismPlacebosAlcohol Abuse TherapyAddictionCravingTrainingBrainAcuteAlcohol ConsumptionAlcohol CueMolecular TargetDouble-Blind MethodCue ReactivityCuesEffective TherapyAlcoholsDiagnosisBehavioralChronicAlcohol Exposure
Grant awards (12)
External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting$301,281
R34 · FY2025 · AA
Proof of concept: diclofenac as a KMO inhibitor in AUD$184,656
R21 · FY2025 · AA · contact PI
External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting$301,281
R34 · FY2024 · AA
Proof of concept: diclofenac as a KMO inhibitor in AUD$223,531
R21 · FY2024 · AA · contact PI
Development of minocycline as a neuroimmune therapy for alcohol use disorder$176,569
K01 · FY2021 · AA · contact PI
Development of minocycline as a neuroimmune therapy for alcohol use disorder$31,420
K01 · FY2021 · AA · contact PI
Development of minocycline as a neuroimmune therapy for alcohol use disorder$176,569
K01 · FY2020 · AA · contact PI
Development of minocycline as a neuroimmune therapy for alcohol use disorder$176,569
K01 · FY2019 · AA · contact PI
Development of minocycline as a neuroimmune therapy for alcohol use disorder$176,569
K01 · FY2018 · AA · contact PI
Development of minocycline as a neuroimmune therapy for alcohol use disorder$187,164
K01 · FY2017 · AA · contact PI
Role of estradiol in women smokers' acute HPA axis hormone response to naltrexone$22,908
F31 · FY2012 · DA · contact PI
Role of estradiol in women smokers' acute HPA axis hormone response to naltrexone$41,800
F31 · FY2011 · DA · contact PI